Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke

Cerebrovascular Diseases

Volumn 26, Issue 3, 2008, Pages 272-276

  Karepov, Vadim ^a   Tolpina, Galina ^a   Kuliczkowski, Wiktor ^b   Serebruany, Victor ^b,c  

^a Meteor Medical Centre   (Israel)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HeartDrug Research Laboratories   (United States)

Author keywords

Aspirin; Platelets; Stroke; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ANALYZER; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE DURATION; DRUG RESPONSE; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; STROKE; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 47549102119     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000147455     Document Type: Article

References (22)

1. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ: PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
2. Boldt J, Huttner I, Suttner S, Kumle B, Piper SN, Berchthold G: Changes of haemostasis in patients undergoing major abdominal surgery - is there a difference between elderly and younger patients? Br J Anaesth 2001;87:435-440.
3. Halil M, Cankurtaran M, Yavuz BB, Ulger Z, Piskinpasa S, Gedik A, Haznedaroglu IC, Kirazli S, Ariogul S: Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007;41:41-45.
4. Assadian A, Lax J, Meixner-Loicht U, Hagmuller GW, Bayer PM, Hubl W: Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 2007;45:1142-1147.
5. Hobikoglu GF, Norqaz T, Aksu H, Ozer O, Erturk M, Destequl E, Akyuz U, Unal Dia S, Narin A: The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007;23:201-206.
6. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336.
7. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J: Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-178.
8. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD: Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
9. Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD: Failure of aspirin treatment after stroke. Stroke 1994;25:275-277.
10. Karepov VG, Tolpina GI: Hyperlipidemia and aspirin resistance in post-stroke patients. 1st International Conference on Hypertension, Lipids, Diabetes and Stroke Prevention, Paris, 2006.
11. Coma-Canella I, Velasco A, Castano S: Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005;101:71-76.
12. Gum PA, Kottke-Marchant R, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
13. Hamsten A: Lipids as a coronary risk factor: analysis of hyperlipidaemias. Postgrad Med J 1993;69(suppl 1):S8-S11.
14. Karepov VG: Aspirin resistance, hyperlipidemia and secondary stroke prevention. Int J Stroke 2006;1(suppl 1):72-73.
15. Porto I, Leone AM, Nanni L, Sciahbasi A, De Vita M, Lanza GA, Andreotti F: Interplay of platelet polymorphisms, risk factors, and von Willebrand factor in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease. Blood Coagul Fibrinolysis 2005;16:97-104.
16. Pamukcu B, Oflaz H, Onur I, Oncul A, Umman B, Koylan N, Bugra Z, Meric M, Nisanci Y: Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007;18:461-465.
17. Bornstein NM, Aronovich BD, Karepov VG, Gur AY, Treves TA, Oved M, Korczyn AD: The Tel Aviv Stroke Registry: 3,600 consecutive patients. Stroke 1996;27:1770-1773.
18. Haubelt H, Anders C, Hellstem P: Can platelet function tests predict clinical efficacy of aspirin? Semin Thromb Hemost 2005;31:404-410.
19. Gurbel PA, Blinden KP, Di Chiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation 2007;115:3156-3164.
20. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res 2004;113:101-113.
21. Durrington PN: Diabetes, hypertension and hyperlipidaemia. Postgrad Med J 1993;69(suppl 1):S18-S29.
22. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001-1005.